SPECIAL REPORT: State of the Pharmaceutical Industry, 2008

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Trends and Their Implications for Stakeholders
• 2008: Charting New Waters
  • The Haves and the Have-Nots: Propelling Companies Toward Novel Options
  • Predicting a Growing Divide
  • Surviving Fallow Periods Will Become More Diffi cult
  • Superimposing the Generic Dimension Widens the Have/Have-Not Divide
  • Coping Strategies Will Force New Business Models
• Personalized Information: Who Will Provide It?
  • Recent Trends in Communicating Information on Drugs and Health Care
  • Providing Unbiased Drug Information
  • The Value of Social Networking
  • Educating Physicians: Evidence-Based Medicine and Counter-Detailing
• Globalization: Threat or Opportunity
  • Expanding into Emerging Pharmaceutical Markets
  • Different Pharmaceutical Markets Developing in China and India
    • No Longer Simply a Matter of Cost
    • Moving Upstream in the R&D Value Chain
  • Japan' s Evolving Pharmaceutical Marketplace
    • Growing Impact of Foreign Pharmaceutical Companies
    • Domestic Japanese Companies: To Merge or Not to Merge?
    • Striving to Stay Independent
• Pharma Pricing 2008: Make or Break?
  • Crumbling Industry Defenses
  • Emboldened Customer Offensives
• Technology Assessment: The Case of Alzheimer' s Drugs
  • Technology Assessments
  • The Case of Alzheimer' s Drugs
  • Actions Going Forward
• Convergence: Are We There Yet?
  • Targeted Therapies
  • Biomarker-Driven Personalized Medicine: The Way Forward in Cancer Therapy
  • An Analysis of Industry Trends in Personalized Medicine
    • Trends Identifi ed by the Diaceutics Google Index
    • Lack of an Appropriate Business Model
    • Convergence
• Industry Action Items Going Forward

Experts Featured:

• John Ansell, M.A., principal, John Ansell Consultancy
• Cheryl Barton, Ph.D., principal, Pharmavision.co.uk
• R. Roman Boutellier, Ph.D., Swiss Federal Institute of Technology, Zurich
• Caroline Fielding, deputy managing director, Virgo Health PR
• Sarah W. Fuller, president, Decision Resources, Inc
• Jeffrey Gruen, M.D., M.B.A., chief medical offi cer, Revolution Health
• Barrie G. James, Ph.D., principal, Pharma Strategy Consulting
• James McDermott, vice president, consulting, Decision Resources, Inc
• Mollie Roth, J.D., corporate counsel, vice president of business development, Diaceutics
• Alexander J. Schicker, M.Sc., Swiss Federal Institute of Technology, Zurich
• Jeffrey Settleman, Ph.D., professor of medicine at Harvard Medical School and director, Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer Center
• Hiroshi Tashiro, M.Sc., research manager of Decision Resources' Tokyo offi ce
• Fredrik Ullman, M.Sc., Swiss Federal Institute of Technology, Zurich
• Prachi Vora, M.P.H., Spectrum program manager, Decision Resources, Inc

Tables:

• 1. Number of Phase III NCEs in Development by the Top Five Pharmaceutical Companies, 2007
• 2. Top Five Pharmaceutical Companies: Impact of Patent Expiry Versus Number of Phase III NCEs in Development
• 3. Globalization of Biotechnology, 2006
• 4. Foreign Multinational Players: Select Japanese Market Strategies and Equity Transfers, 2002-2007
• 5. Mergers and Acquisitions of Key Japanese Pharmaceutical Companies, 2002-2007
• 6. Spectrum Scorecard: Pharma Action Items Going Forward, 2008

Figures:

• 1. 2008' s Pharmaceutical Industry: Wrestling with New Options
• 2. Number of Products Achieving Global Sales Thresholds, 2006
• 3. Mature and Emerging Pharmaceutical Markets, 2007
• 4. Globalization: Rapidly Developing Asian Pharmaceutical Markets
• 5. China and India: Pharmaceutical Market Comparison
• 6. Number of Drugs Launched in the Japanese Market by Major Companies, 2002-2006
• 7. Tyrosine Kinases and Their Targeted Therapies
• 8. Diaceutics Google Index (DGi) for Personalized Medicine, June 2005-June 2007
• 9. Diaceutics Google Index (DGi) for Personalized Medicine Topics